Profile Response Detail

Molecular Profile KRAS mutant
Therapy RO4987655
Indication/Tumor Type colorectal cancer
Response Type no benefit
Create By smockus
Update By spatt


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant colorectal cancer no benefit RO4987655 Phase I Actionable In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927). 24947927
PubMed Id Reference Title Details
(24947927) Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Full reference...